Sol-Gel out-licenses rights to Twyneo in China and Israel

Israeli dermatology company Sol-Gel Technologies (Nasdaq: SLGL) has signed an agreement with Beimei Pharma for the commercialization of Twyneo (tretinoin/benzoyl peroxide) in China, Hong Kong, Macau, Taiwan and Israel.

Under the terms of the agreement, Shenzhen-based Beimei gains rights to exclusively commercialize the product, in return for upfront and milestone payments of $10 million and up to $5 million in royalties.

Chief executive Alon Seri-Levy said: “This agreement demonstrates the potential of Twyneo, and we expect to announce other agreements regarding the commercialization of both our FDA-approved assets, Twyneo and Epsolay, in other territories.”